NCT06108479 - Study of DF6215 in Patients with Advanced Solid Tumors | Biotech Hunter

Enrollment

255

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2027

Conditions

Solid Tumor, AdultSolid Tumor Cancer

Interventions

DRUG

DF6215

Immunotherapy (cytokine) targeting effector cells.

DRUG

pembrolizumab

Anti-PD-1 immunotherapy agent

DRUG

KEYTRUDA®

Anti-PD-1 immunotherapy agent

Trial Locations (21)

3199

RECRUITING

Peninsula and South East Oncology Medical (PASO), Frankston

5000

RECRUITING

Cancer Research SA (CRSA), Adelaide

10016

RECRUITING

NYU Langone Health, New York

13005

RECRUITING

CHU de Marseille - Hôpital de la Timone, Marseille

13009

RECRUITING

Institut Paoli-Calmettes, Marseille

21000

RECRUITING

Centre Georges François Leclerc, Dijon

31100

RECRUITING

Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse

33000

RECRUITING

Institut Bergonié, Bordeaux

33075

RECRUITING

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

33606

RECRUITING

Tampa General Hospital, Tampa

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

SCRI Oncology Partners, Nashville

44805

RECRUITING

Institut de Cancérologie de l'Ouest - Saint-Herblain - Site René Gauducheau, Saint-Herblain

69495

NOT_YET_RECRUITING

Hôpital Lyon-Sud, Pierre-Bénite

75005

RECRUITING

Institut Curie, Paris

86000

RECRUITING

Centre Hospitalier Universitaire de Poitiers, Poitiers

90025

RECRUITING

The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

92093

RECRUITING

University of California San Diego Moores Cancer Center, San Diego

92868

RECRUITING

University of California Irvine Medical Center, Orange

02903

RECRUITING

Lifespan - Rhode Island Hospital, Providence